Abstract | OBJECTIVES: METHODS: RESULTS: The mean symptom duration was 11.33 ± 10.6 months (range, 2-34 months). The cohort comprised (1) primary idiopathic polymyositis (n = 1), (2) primary idiopathic dermatomyositis (n = 1), (3) childhood type associated with vasculitis (n = 1), and (4) associated with collagen vascular disease (n = 6). All patients improved and became clinically asymptomatic after a mean period of 12.33 ± 6.5 months (range, 4-24 months); 5 remained asymptomatic at the end of a median follow-up period of 22 months. All patients received concomitant steroid therapy, and in 6, steroids could be tapered after the initiation of IV pulse cyclophosphamide therapy. CONCLUSIONS:
|
Authors | M Nagappa, A B Taly, S Sinha, N Gayathri, P S Bindu, A Mahadevan, T Yasha |
Journal | Journal of clinical neuromuscular disease
(J Clin Neuromuscul Dis)
Vol. 14
Issue 4
Pg. 161-8
(Jun 2013)
ISSN: 1537-1611 [Electronic] United States |
PMID | 23703010
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Cyclophosphamide
- Desonide
|
Topics |
- Adolescent
- Adult
- Anti-Inflammatory Agents
(therapeutic use)
- Cohort Studies
- Cyclophosphamide
(therapeutic use)
- Dermatomyositis
(complications, drug therapy)
- Desonide
(therapeutic use)
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Polymyositis
(complications, drug therapy)
- Young Adult
|